Exercise Oncology Clinic Pilot Feasibility Trial
Part of paid clinical trials in Iowa City, Iowa.
- Sponsor
- Jess S. Gorzelitz
- Study ID
- NCT07765927
- Status
- Recruiting
Conditions
- Breast Cancer
- Gynecologic Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Supervised, Personalized Exercise Program — OTHERSessions will include both resistance (strength) training and aerobic exercise, delivered under the guidance of trained personnel to ensure appropriate technique, progression, and safety.
Study Details
The purpose of this pilot study is to test a supervised exercise program for adults with a history of breast or gynecologic cancer to see if it is safe, helpful, and easy to take part in.
Key Dates
- First listed
- Aug 14, 2026
- Start date
- Aug 3, 2026
- Status verified
- Aug 2026
- Primary completion
- Dec 15, 2026
- Completion
- Apr 15, 2027
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Supervised, Personalized Exercise ProgramThe clinic will conduct comprehensive patient assessments, develop personalized exercise programs, and monitor progress through fitness evaluations and wearable devices.
Primary Outcome Measure
Recruitment rate calculated as the number of participants enrolled divided by the number approached or referred over the study period. [ Time Frame: Recruitment period which will start at day 1 through two months ]
Central Contacts
- Jess Gorzelitz, PhD, MS(319) 467-0849
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Iowa Health Care | Iowa City | Iowa | 52242 |
Find similar trials in Iowa City, IA
By condition
By specialty
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing TumorsPHASE1 · Recruiting · Orano Med Theranostics, SAS · Iowa City, Iowa
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerPHASE1 · Recruiting · Olema Pharmaceuticals, Inc. · Gilbert, Arizona